Amelia Nell

Amelia Nell supports clients with evidence-based research and analysis that spans healthcare sectors and stakeholders.

With a background in health policy and legislation, she contributes to the development of client analysis and insights.

Amelia has a held a variety of research and policy positions, most recently at the Children’s Defense Fund where she tracked healthcare legislation and regulatory action and analyzed national disparities in children’s healthcare access. As a researcher with the Schroeder Center for Health Policy at the College of William & Mary, she analyzed the rate of potentially avoidable hospitalizations by insurance payer-type. Additionally, at the Virginia Center for Health Innovation, she compiled research on state HPV vaccination initiatives and strategies for eliminating wasteful medical practices.

Amelia has a BA in public policy and American studies from the College of William & Mary.

Authored Content

The intersection of upcoming changes to drug pricing metrics will require new methods of calculating and reporting government pricing with implications for net pricing and contracting strategies.

Since passage of the Affordable Care Act (ACA), 36 states and DC have expanded Medicaid. Some of the remaining states may reconsider expansion given new federal funding incentives.

A second reconciliation package could include significant drug pricing reforms as a means to pay for permanent coverage expansion and other top priorities.

Amid the continuing pandemic and calls for healthcare reform, the new administration seeks to confront the myriad public health issues facing our country today.

The outcome of Georgia’s runoff election—resulting in a Democratic majority in the Senate—combined with the existing Democratic majority in the House and incoming Biden administration, significantly changes the policy outlook for 2021.

State Medicaid programs are likely to face significant budget impacts from emerging cell and gene therapies and may seek to implement a variety of strategies to manage utilization and address provider reimbursement and financing challenges.

Avalere analysis finds that patients with Crohn’s disease who experience a negative outcome when required to step through a plan’s preferred product may face higher upfront out-of-pocket (OOP) costs and could increase costs to payers.

The November 2020 election is widely anticipated to have important implications for how the US responds to COVID-19.

As our healthcare industry rapidly evolves to address the COVID-19 pandemic, keep track of new resources and policies affecting patients and providers with the COVID-19 guide below.

On March 2, the Supreme Court (SCOTUS) announced that it will review an appeal of the 5th Circuit Court of Appeal’s decision in Texas v. Azar regarding the legality of the Affordable Care Act’s (ACA’s) individual mandate and other provisions.